We hypothesized that follistatin overexpression inhibits immune responses, and thus promotes immunotherapy resistance, through the neutralization of TGF-β superfamily ligands, such as Activin A, which play a critical role in regulating multiple cells of the tumor microenvironment (TME), including cancer cells and immunocytes [17, 18]. The gene discussed is FST; the disease is neoplasm.